A population-based nested case-control study in Taiwan: Use of 5α-Reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia

Oncologist

Volumn 17, Issue 7, 2012, Pages 986-991

  Liang, Ji An ^a,c   Sun, Li Min ^d   Lin, Ming Chia ^b,e   Chang, Shih Ni ^b,c,f   Sung, Fung Chang ^b,c   Muo, Chih Hsin ^b,c   Kao, Chia Hung ^a,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d ZUOYING ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^e E DA HOSPITAL   (Taiwan)

^f INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

5 Reductase inhibitors; Benign prostate hyperplasia; Prostate cancer

Indexed keywords

DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; TAIWAN;

5-ALPHA REDUCTASE INHIBITORS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TAIWAN;

EID: 84864040005     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0464     Document Type: Article

References (25)

1. Pritchard CC, Nelson PS. Gene expression profiling in the developing prostate. Differentiation 2008;76: 624-640.
2. Nelson PS, Clegg N, Arnold H et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 2002;99:11890-11895.
3. Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol 2004;6:S31-S39.
4. Theoret MR, Ning YM, Zhang JJ, et al. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011;365:97-99.
5. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224.
6. Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-1202.
7. Akaza H, Kanetake H, Tsukamoto T et al. Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study. Jpn J Clin Oncol 2011;41:417-423.
8. Lu JF, Hsiao WC. Does universal health insurance make health care unaffordable? Lessons from Taiwan. Health Aff (Millwood) 2003;22:77-88.
9. Cancer Statistics Annual Report. Taiwan Cancer Registry. Available at http://tcr.cph.ntu.edu.tw/main. php?Page_N2. Accessed November 16, 2011.
10. Edwards BK, Ward E, Kohler BA et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-573.
11. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005;41:834-845.
12. Liang JA, Sun LM, Yeh JJ et al. The association between malignancy and end-stage renal disease in Taiwan. Jpn J Clin Oncol 2011;41:752-757.
13. Ross RK, Bernstein L, Lobo RA et al. 5-Alphareductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339: 887-889.
14. Giovannucci E, Stampfer MJ, Krithivas K et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997;94:3320-3323.
15. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002;52:213-235.
16. Rittmaster RS. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab 2008;22: 389-402.
17. Andriole GL, Guess HA, Epstein JI et al. Treatment with finasteride preserves usefulness of prostate specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo controlled clinical trial. Urology 1998;52:195-202.
18. Andriole GL, Bautista M, Crawford D et al. Prostate cancer (CAP) detection in the medical therapy of prostatic symptoms (MTOPS) trial. Abstract presented at: American Urological Association Annual Meeting, April 26-May 1 2003, Chicago, IL.
19. Roehrborn CG, Nickel JC, Andriole GL et al. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Urology 2011; 78:641-646.
20. Traish AM, Hassani J, Guay AT et al. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011;8:872-884.
21. Hamilton RJ, Freedland SJ. 5α-reductase inhibitors and prostate cancer prevention: where do we turn now? BMC Med 2011;9:105.
22. Parekh DJ. Prostate cancer prevention with 5 alpha-reductase inhibitors. Recent Results Cancer Res 2011;188:109-114.
23. Hamilton RJ, Kahwati LC, Kinsinger LS. Knowledge and use of finasteride for the prevention of prostate cancer. Cancer Epidemiol Biomarkers Prev 2010;19: 2164-2171.
24. Chuang AY, Chang SJ, Horng CF et al. Study of prostate cancer pathologic features in Chinese populations. Urology 2007;69:915-920.
25. Gormley GJ. Finasteride: a clinical review. Biomed Pharmacother 1995;49:319-324.